Pharmaceuticals Trio Draw Buy Ratings Ahead of 2026 Catalysts
A trio of small-cap biotechs—X4 Pharmaceuticals, Immuneering, and Tango Therapeutics—are attracting new and renewed a...
This page offers a quick comparison of Index Fund and Target Date for retirement, with tips on matching your plans and risk tolerance.
24,517 articlesA trio of small-cap biotechs—X4 Pharmaceuticals, Immuneering, and Tango Therapeutics—are attracting new and renewed a...
Palantir delivered an 85% year-over-year revenue surge in Q1 2026 and lifted full-year targets, but the shares are do...
A Nike brand moat argument resurfaces as investors weigh the stock's downside and potential upside. A Nike analyst po...
A 12-night Wembley residency turns a stadium tour into a financial study for fans and investors alike. This article b...
IBM faces a tougher 2026 as AI and cloud shifts hit margins. With a sharp price drop and a sizable upside versus cons...
Ally Financial is off to a challenging start in 2026, with shares down as inflation and tariff risks bite auto lendin...
Grocery Outlet faces supply-chain and affordability pressures, while Scholastic gauges upside; analysts adjust target...
A State Street strategist says the Fed will cut rates three times in 2026, a view that clashes with current market pr...
Rocket Lab stock remains volatile but disciplined investors see a path to a $150 milestone by 2027 as backlog grows a...
A biotech growth stock has surged 70% this year as it heads into pivotal phase 3 data and regulatory steps. Here’s wh...
Lucid shares rebound for a second day after the CEO refutes bankruptcy and take-private rumors, with investors eyeing...
Two overlooked levers let the Fed tighten policy without altering the federal funds rate. This guide explains how the...